Fortitude Family Office’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Fortitude Family Office's VRTX Position: Q2 2026 in Review
Fortitude Family Office reduced its Vertex Pharmaceuticals (VRTX) stake by 4% in Q2 2026, selling an estimated $1.33K and leaving 72 shares worth $35.8K. The position accounts for 0.01% of the portfolio, ranked #359.
Fortitude Family Office first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $37.3K in Q1 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Fortitude Family Office held 72 shares of Vertex Pharmaceuticals worth $35.8K as of Q2 2026.
- Fortitude Family Office sold 3 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.33K.
- Vertex Pharmaceuticals made up 0.01% of Fortitude Family Office's portfolio in Q2 2026, its #359 holding.
- Fortitude Family Office first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
- Fortitude Family Office's Vertex Pharmaceuticals position peaked at $37.3K in Q1 2025.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.